Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 629 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 629 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the sale, the executive vice president now directly owns 68,212 shares in the company, valued at $8,611,765. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Michael Jon Brown also recently made the following trade(s):

• On Thursday, March 28th, Michael Jon Brown sold 2,624 shares of DexCom stock. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96.

DexCom Price Performance

Shares of DXCM stock opened at $128.37 on Friday. The firm has a fifty day moving average of $132.11 and a two-hundred day moving average of $119.96. The firm has a market cap of $51.05 billion, a P/E ratio of 82.82, a P/E/G ratio of 2.15 and a beta of 1.23. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. As a group, research analysts anticipate that DexCom, Inc. will post 1.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on DXCM shares. Raymond James lifted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Royal Bank of Canada began coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. UBS Group raised their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Canaccord Genuity Group boosted their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Citigroup increased their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average price target of $141.67.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently modified their holdings of DXCM. DSM Capital Partners LLC acquired a new stake in shares of DexCom in the 4th quarter valued at about $28,000. Valley National Advisers Inc. raised its stake in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co acquired a new stake in shares of DexCom in the 1st quarter valued at about $32,000. MV Capital Management Inc. raised its stake in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 138 shares in the last quarter. Finally, Smithfield Trust Co raised its stake in DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after acquiring an additional 165 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.